The global respiratory inhalers market attained a value of USD 35.31 Billion in 2025. The market is further expected to grow in the forecast period of 2026-2035 at a CAGR of 5.40%, to reach USD 59.75 Billion by 2035.
Base Year
Historical Period
Forecast Period
The prevalence of chronic obstructive pulmonary disease (COPD) is estimated to be 12% in the general population, ranking as the 3rd leading cause of global mortality.
In June 2023, Gilbert Technologies raised EUR 7 million in Seed and Series A funding to accelerate the development of its Electro Hydrodynamic Atomization (EHDA) technology and smart precision inhaler solutions for lung patients.
One of the significant market trends is the development and use of inhalers that combine multiple medications in a single device such as the FDA-approved asthma rescue inhaler Airsupra.
Compound Annual Growth Rate
5.4%
Value in USD Billion
2026-2035
*this image is indicative*
Respiratory inhalers are handheld, portable medical devices that allow the delivery of medication directly to the lungs through the individual’s mouth. They are usually employed to treat asthma and chronic obstructive pulmonary disease (COPD). The inhalation route of administration offers a distinct advantage by maximizing the concentration of the drug in the target tissue, providing the highest potential therapeutic effect.
The respiratory inhalers market is driven by the rising cases of respiratory disorders propelling the demand for efficient inhaler devices. The introduction of innovative products such as smart inhalers by market leaders is also expected to fuel the market expansion in coming years. Furthermore, the rising healthcare expenditure and heightened patient awareness are likely to augment the market demand for respiratory inhalers.
Advancements in inhaler technology, integration of digital health solutions, increased focus on combination therapies, and environmental sustainability initiatives comprise some of the key trends and developments in the market.
GSK is actively investing to redevelop its Ventolin (salbutamol) inhaler into a next-generation lower carbon propellant, which currently accounts for 49% of the company’s carbon footprint, and is prescribed to almost 35 million patients. The company announced its plan to begin the Phase III trials of the metered dose inhaler in 2024 and regulatory submissions in 2025 on getting positive results. If successful, the next-generation propellant technology is estimated to reduce greenhouse gas emissions by 90%.
Teva Pharmaceutical Industries Ltd., Teva UK launched a new inhaler system GoResp Digihaler (budesonide/formoterol fumarate dihydrate) in the United Kingdom. The innovative device, with features like built-in sensors and Bluetooth technology, is designed for COPD and asthma patients, allowing self-management of the condition and sharing of data with healthcare professionals.
Gilbert Technologies, a Dutch medical technology manufacturer, raised EUR 7 million in Seed and Series A funding. The funds were expected to be used in supporting the development of Electro Hydrodynamic Atomization (EHDA) technology and smart precision inhaler solutions for lung patients with severe asthma, cystic fibrosis (CF), and other disease states.
AstraZeneca, The United States Food and Drug Administration (FDA) granted approval for Airsupra, an asthma rescue inhaler for adults 18 and older. It delivers two drugs, albuterol (opens up airways) and budesonide (treats inflammation) simultaneously. The product, developed as a collaborative effort between AstraZeneca and Avillion, is the first rescue inhaler that can manage both symptoms and inflammation associated with the condition.
The market is experiencing significant growth driven by the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. These conditions fuel the demand for respiratory inhalers to manage the symptoms. Moreover, the rising air pollution levels and the growing geriatric population is more susceptible to respiratory disorders are some of the factors bolstering market growth.
The respiratory inhalers market size is poised to witness a steady expansion supported by rising disposable incomes, heightened patient awareness towards respiratory health, and increased initiatives by the government to improve patient outcomes. Moreover, the increased strategic partnerships between the key market players to introduce technologically advanced inhaler systems in the market are likely to augment market size in the forecast period.
"Global Respiratory Inhalers Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Breakup by Product
Breakup by Type
Breakup by Indication
Breakup by End User
Breakup by Region
The key market players are contributing to the respiratory inhalers market growth through strategic mergers and acquisitions initiatives, novel product launches, and continuous research and development efforts aimed at bringing technological advancements in the market.
| Company | Year Founded | Headquarters | Products/Services |
| Novartis AG | 1996 | Basel, Switzerland | Offers inhalable drugs and devices for respiratory conditions, including COPD and asthma |
| AstraZeneca | 1999 | Cambridge, United Kingdom | Provides a range of inhalers for asthma and COPD treatment, including Symbicort |
| GSK plc | 2000 | Brentford, United Kingdom | Manufactures a variety of inhalers, such as Ventolin and Advair |
| Chiesi Farmaceutici SpA | 1935 | Parma, Italy | Specializes in products for respiratory conditions, including inhalers for asthma and COPD, such as NEXThaler (dry powder inhaler) |
Other key players in the market include Lupin, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH, GLENMARK PHARMACEUTICALS LTD, Presspart Verwaltungs GmbH, Rossmax International Ltd, HELTMAN Medikal A.S., and Microlife Corporation.
North America is predicted to lead the market share for respiratory inhalers, owing to the presence of advanced healthcare infrastructure and better accessibility to innovative inhaler products. Additionally, with pioneering market leaders integrating latest technologies in inhaler systems, the demand for respiratory inhalers to treat and manage respiratory disorders is expected to rise in the coming years.
Europe also holds a high market value which can be attributed to the rising cases of COPD in the region, estimated to carry an annual direct cost of around EUR 38.6 billion . In addition, the existence of premium research institutes and medical device companies in the region plays a pivotal role in accelerating the growth of the market.
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 35.31 Billion in 2025 driven by the rising prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) across the 8 major markets.
The market is anticipated to grow at a CAGR of 5.40% during the forecast period of 2026-2035, likely to reach a market value of USD 59.75 Billion by 2035.
Technological advancements in inhaler systems and the increased healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is the surge in innovative product launches. In August 2023, Teva UK launched a new inhaler system GoResp Digihaler in the United Kingdom, with features like built-in sensors and Bluetooth technology designed for COPD and asthma patients, allowing self-management of the condition and sharing of data with healthcare professionals.
Based on the product, the market comprises dry powder inhalers, metered dose inhalers, soft mist inhalers, and nebulizers, which are further divided into jet nebulizers, ultrasonic nebulizers, and mesh nebulizers.
Based on the type, the market is segmented into conventional inhalers and smart inhalers.
End-users of the market are hospitals, clinics, homecare settings, and other healthcare facilities
Indications for respiratory inhalers include asthma and chronic obstructive pulmonary disease (COPD).
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
Key players involved in the market are Novartis AG, AstraZeneca, GSK plc, Chiesi Farmaceutici SpA, Lupin, Teva Pharmaceutical Industries Ltd, OMRON Corporation, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH, GLENMARK PHARMACEUTICALS LTD, Presspart Verwaltungs GmbH, Rossmax International Ltd, HELTMAN Medikal A.S., and Microlife Corporation.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Type |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share